We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Inovio’s Vaccine Candidate Shows Promise in Early Trial
Inovio’s Vaccine Candidate Shows Promise in Early Trial
Inovio Pharmaceuticals has released data from the phase 1 clinical trial of its COVID-19 vaccine candidate showing it was safe and well-tolerated and induced immune responses in a majority of participants.